Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Gail Sloan, Macey Johnson, III, Matt Sargent, Howard McLeod

Premium

BioTheranostics has added three new employees to its senior management roster, including Gail Sloan as chief financial officer; Macey Johnson, III, as VP of managed care and reimbursement; and Matt Sargent as commercial leader of the Breast Cancer Index molecular test. These three will play a key role in BioTheranostics efforts to further expand commercial activities for its Breast Cancer Index product.

Prior to joining BioTheranostics, Sloan was CFO and VP of finance at La Jolla Pharmaceutical where she helped raise more than $330 million through private placements and public offerings. Johnson brings to BioTheranostics her many years of experience working in various roles at Genomic Health and Genentech. Sargent most recently was VP of oncology sales for Caris Life Sciences.


Howard McLeod is the new medical director of the Personalized Medicine Institute at the Moffitt Cancer Center. Previously, McLeod was the Fred Eshelman Distinguished Professor of Pharmacogenomics and Individualized Therapy at the University of North Carolina, Chapel Hill.

Additionally, he is the principal investigator for the CREATE Pharmacogenetics Research Network and a member of the Pharmacogenetics Research Network. McLeod directs the Pharmacogenetics for Every Nation Initiative, an effort that aims to help developing countries use genetic information to improve national drug formulary decisions.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.